Leonard Zehr, Author at BioTuesdays

Markets

Maxim cuts Aridis Pharma to hold

Maxim Group downgraded Aridis Pharmaceuticals (NASDAQ:ARDS) to “hold” from “buy” and removed its price target, citing capital concerns and key clinical programs. The stock closed at $2.19 on Aug. 15. In a 10-Q report...

August 16, 2022

Developments

iBio updates development of next-gen COVID-19 vaccine candidate

iBio (NYSEA:IBIO) provided an update on IBIO-202, its next-generation vaccine candidate under development for multi-variant COVID-19 disease. Unlike first-generation COVID vaccines that seek to provide immunity by...

August 16, 2022

Feature

Zymeworks targeting cancer with next-gen multifunctional biotherapeutics

Zymeworks (NYSE:ZYME) is leading a paradigm shift developing next-generation multifunctional antibodies and antibody drug conjugates, with an initial focus on HER2-targeted therapies to treat cancer.

August 16, 2022

Markets

Cantor cuts TerrAscend to neutral on model update post Q2 miss

Cantor Fitzgerald downgraded TerrAscend (OTCQX:TRSSF) to “neutral” from “overweight” and reduced its price target to $2.85 from $6.45 on lower estimates and sectoral derating. The stock closed at $2.40 on Aug. 11...

August 12, 2022

Developments

Rani Therapeutics posts positive Phase 1 results in osteoporosis

Rani Therapeutics (NASDAQ:RANI) reported positive topline results from the single-ascending dose portion of its Phase 1 clinical study of RT-102, a RaniPill capsule containing a proprietary formulation of human...

August 11, 2022

Developments

Blue Water Vaccines in $10-million private placement

Blue Water Vaccines (NASDAQ:BWV) entered into definitive agreements with several healthcare-focused institutional investors for the purchase of 3,683,280 common shares of the company in a private placement priced at-the...

August 9, 2022

Feature

Brickell Biotech pivots to make fresh tracks in autoimmune, inflammatory medicine

After selling its late-stage dermatology program in May 2022, Brickell Biotech (NASDAQ:BBI) has pivoted its focus to developing differentiated therapeutics for the treatment of autoimmune, inflammatory and other...

August 9, 2022

Markets

Cantor cuts Galmed to neutral on limited insights into programs

Cantor Fitzgerald downgraded Galmed Pharmaceuticals (NASDAQ:GLMD) to “neutral” from “overweight” and slashed its price target to 70 cents from $5 after the company announced a business update along with financials for...

August 4, 2022

Developments

Sigyn Therapeutics to begin trading on OTCQB today

Shares of Sigyn Therapeutics (OTCQB:SIGY) will begin trading on the OTCQB Venture Exchange at the market open today. The company’s securities, which previously traded on the OTC Pink Market, will continue to trade...

August 3, 2022

Developments

Qualigen posts positive readout in triple negative breast cancer in vivo model

Qualigen Therapeutics (NASDAQ:QLGN) completed its in vivo efficacy analysis of QN-247 in solid tumors, with data demonstrating robust efficacy and no safety signals in a triple negative breast cancer (TNBC) model...

August 2, 2022

Author - Leonard Zehr

Maxim cuts Aridis Pharma to hold

iBio updates development of next-gen COVID-19 vaccine candidate

Zymeworks targeting cancer with next-gen multifunctional biotherapeutics

Cantor cuts TerrAscend to neutral on model update post Q2 miss

Rani Therapeutics posts positive Phase 1 results in osteoporosis

Blue Water Vaccines in $10-million private placement

Brickell Biotech pivots to make fresh tracks in autoimmune, inflammatory medicine

Cantor cuts Galmed to neutral on limited insights into programs

Sigyn Therapeutics to begin trading on OTCQB today

Qualigen posts positive readout in triple negative breast cancer in vivo model

General

More